
| | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with Pembrolizumab in Adult Subjects with Advanced or Metastatic Solid Tumors David Luo;1 Raghad Abdul-Karim;2 Arun Azad;3 Joanna Bendell;4 Hui Gan;5 Filip Janku;6 Shiraj Sen;7 Tira Tan;8 Judy Wang;9 Lisa Schechet;1 Lauren Baker;1 Joseph Leveque;1 Tarek Meniawy10 1Synthorx, Inc., La Jolla, CA;2NEXT Oncology, Texas Oncology, San Antonio, Tx;3Peter MacCallum Cancer Centre, Melbourne, Victoria, Aus;4Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;5Austin Health, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Aus;6Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;7Sarah Cannon Research Institute at HealthONE, Denver, CO;8Division of Medical Oncology, National Cancer Centre Singapore;9Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota FL;10Linear Clinical Research, Nedlands, Western Australia, Australia |